SEARCH

SEARCH BY CITATION

References

  • 1
    Legato MJ, Bilezikian JP. Principles of gender-specific medicine. Amsterdam, Boston: Elsevier Academic Press; 2004;2:p.11245.
  • 2
    Council of Europe, Committee of Ministers. Recommendation CM/Rec(2008)1 of the committee of ministers to member states on the inclusion of gender differences in health policy. ( http://www.coe.int/t/e/human_rights/equality/PDF_Rec_2008_1_en.pdf ).
  • 3
    RiederA, LohffB (editors). Gender Medicine. Geschlechtsspezifische Aspekte für die klinische Praxis. Wien, New York: Springer;2008;2:pp.1542.
  • 4
    Ramasubbu K, Gurm H, Litaker D. Gender bias in clinical trials: do double standards still apply? J Womens Health Gend Based Med 2001;8:75764.
  • 5
    Auryan S, Itamar R. Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diab Obes Metab 2008;10:113556.
  • 6
    Legato MJ, Gelzer A, Goland R, Ebner SA, Rajan S, Villagra V et al. writing group for the partnership for gender-specific medicine. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006;3:13158.
  • 7
    Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S144.
  • 8
    International Diabetes Federation. Diabetes Atlas. Prevalence estimates of diabetes mellitus (DM) – European Region. 3rd ed. International Diabetes Federation, Brussels; 2006 ( http://www.eatlas.idf.org/ ).
  • 9
    Williams JW, Zimmet PZ, Shaw JE, De Courten MP, Cameron AJ, Chitson P et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?. Diab Med 2003;20:91520.
  • 10
    DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003;26:619.
  • 11
    Ferrara A, Peng T, Kim C. Trends in postpartum diabetes screening and subsequent diabetes and impaired fasting glucose among women with histories of gestational diabetes mellitus: A report from the Translating Research Into Action for Diabetes (TRIAD) Study. Diabetes Care 2009;32:26974.
  • 12
    WHO Regional Office for Europe. The challenge of obesity in the WHO European Region and the strategies for response: summary. BrancaF, NikogosianH, LobsteinT, editors;2007 ( http://www.euro.who.int/document/e89858.pdf ).
  • 13
    Berrahmoune H, Herbeth B, Samara A, Marteau JB, Siest G, Visvikis-Siest S. Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the stanislas study. Int J Obes (Lond) 2008;32:127988.
  • 14
    Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al. EPIC study group. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359: 210520.
  • 15
    Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008;108:27280.
  • 16
    Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004;89:25839.
  • 17
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006;332:738.
  • 18
    Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31:1898904.
  • 19
    Qiao Q, DECODE Study Group. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006;49:283746.
  • 20
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:24449.
  • 21
    Ford ES, Schulze MB, Pischon T, Bergmann M, Joost HG, Boeing H. Metabolic syndrome and risk of incident diabetes: findings from the European prospective investigation into cancer and nutrition-potsdam study. Cardiovasc Diabetol 2008;7:35.
  • 22
    Anderwald Ch, Krebs M, Promintzer-Schifferl M, Luger A, Kautzky-Willer A, Anderwald-Stadler M et al. Glukoseresorption während des oralen Glukosetoleranztests bei Glukose-toleranten Frauen und Männern. Wien Klin Wochenschr 2008;120(Suppl 5):3.
  • 23
    Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007;147:14955.
  • 24
    Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;58:498504.
  • 25
    Kirchengast S, Schober E. Obesity among female adolescents in Vienna, Austria–the impact of childhood weight status and ethnicity. BJOG 2006;113:118894.
  • 26
    Anderson SE, Economos CD, Must A. Active play and screen time in US children aged 4 to 11 years in relation to sociodemographic and weight status characteristics: a nationally representative cross-sectional analysis. BMC Public Health 2008;8:366.
  • 27
    Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Impaired glucose tolerance for atherosclerosis and diabetes study. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Diabetes Care 2003;26:86874.
  • 28
    Nuutila P, Knuuti MJ, Mäki M, Laine H, Ruotsalainen U, Teräs M et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes 1995;44:316.
  • 29
    Clausen JO, Borch-Johnsen K, Ibsen H, Bergman RN, Hougaard P, Winther K et al. Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 1996;98:1195209.
  • 30
    Kautzky-Willer A, Thomaseth K, Clodi M, Ludvik B, Waldhäusl W, Prager R et al. Beta-cell activity and hepatic insulin extraction following dexamethasone administration in healthy subjects. Metabolism 1996;45:48691.
  • 31
    Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF et al. Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 1997;20:171723.
  • 32
    Kautzky-Willer A, Pacini G, Ludvik B, Schernthaner G, Prager R. Beta-cell hypersecretion and not reduced hepatic insulin extraction is the main cause of hyperinsulinemia in obese nondiabetic subjects. Metabolism 1992;41:130412.
  • 33
    Kautzky-Willer A, Pacini G, Weissel M, Capek M, Ludvik B, Prager R. Elevated hepatic insulin extraction in essential hypertension. Hypertension 1993;21:64653.
  • 34
    Ludvik BH, Mahdjoobian K, Waldhaeusl W, Hofer A, Prager R, Kautzky-Willer A et al. The effect of Ipomoea batatas (Caiapo) on glucose metabolism and serum cholesterol in patients with type 2 diabetes: a randomized study. Diabetes Care 2002;25:23940.
  • 35
    Yamaguchi S, Yamada Y, Matsuo H, Segawa T, Watanabe S, Kato K et al. Gender differences in the association of gene polymorphisms with type 2 diabetes mellitus. Int J Mol Med 2007;19:6317.
  • 36
    American Diabetes Association. Standards of medical care in diabetes–2009. Diabetes Care 2009;32(Suppl 1):S1361.
  • 37
    Toulis KA, Goulis DG, Kolibianakis EM, Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertil Steril 2008; doi: DOI: 10.1016/j.fertnstert.2008.06.045.
  • 38
    Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:192935.
  • 39
    Kautzky-Willer A, Bancher-Todesca D, Weitgasser R, Prikoszovich T, Steiner H, Shnawa N et al. The impact of risk factors and more stringent diagnostic criteria of gestational diabetes on outcomes in central European women. J Clin Endocrinol Metab 2008;93:168995.
  • 40
    Dorner T, Rathmanner T, Lechleitner M, Schlögel R, Roden M, Lawrence K et al. Public health aspects of diabetes mellitus–epidemiology, prevention strategies, policy implications: the first Austrian diabetes report. Wien Klin Wochenschr 2006;118:5139.
  • 41
    Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among US adolescents: National health and nutrition examination survey 2005–2006. Diabetes Care 2009;32:3427.
  • 42
    Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J et al. Diabetes Prevention Program. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008;31:141621.
  • 43
    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393403.
  • 44
    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P et al. Diabetes prevention program research group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142:32332.
  • 45
    Ratner RE, Christophi CA, Metzger BE, Dabelea D, Bennett PH, Pi-Sunyer X et al. Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008;93:47749.
  • 46
    Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P et al. Finnish diabetes prevention study group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:134350.
  • 47
    Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J et al. Finnish diabetes prevention study group. The Finnish diabetes prevention study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:32306.
  • 48
    Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:53744.
  • 49
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:20727.
  • 50
    Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796803.
  • 51
    Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:51722.
  • 52
    DREAM (Diabetes reduction assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096105.
  • 53
    McDonald SD, Yusuf S, Sheridan P, Anand SS, Gerstein HC. Diabetes reduction assessment with ramipril and rosiglitazone medication trial investigators. Dysglycemia and a history of reproductive risk factors. Diabetes Care 2008;31:16358.
  • 54
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:14553.
  • 55
    Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity program investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:4853.
  • 56
    Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B et al. CHARM program investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Arch Intern Med 2008;168:1699704.
  • 57
    Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:87586.
  • 58
    Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V et al. The study on cognition and prognosis in the elderly (SCOPE) – major CV events and stroke in subgroups of patients. Blood Press 2005;14:317.
  • 59
    Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:205868.
  • 60
    Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study. Circulation 2001;103:35762.
  • 61
    Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:15561.
  • 62
    Karlsson J, Taft C, Sjöström L, Torgerson JS, Sullivan M. Psychosocial functioning in the obese before and after weight reduction: construct validity and responsiveness of the Obesity-related Problems scale. Int J Obes Relat Metab Disord 2003;27:61730.
  • 63
    Wang GJ, Volkow ND, Telang F, Jayne M, Ma Y, Pradhan K et al. Evidence of gender differences in the ability to inhibit brain activation elicited by food stimulation. Proc Natl Acad Sci USA 2009;106:124954.
  • 64
    Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:128899.
  • 65
    Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA 2004;292:22438.
  • 66
    Handisurya A, Riedl M, Vila G, Maier C, Clodi M, Prikoszovich T et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg 2009; doi: DOI: 10.1007/s11695-009-9882.y.
  • 67
    Kautzky-Willer A, Pacini G, Tura A, Bieglmayer C, Schneider B, Ludvik B et al. Increased plasma leptin in gestational diabetes. Diabetologia 2001;44:16472.
  • 68
    Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 2004;27:17217.
  • 69
    Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003; 52:23943.
  • 70
    Ahmed ML, Ong KK, Watts AP, Morrell DJ, Preece MA, Dunger DB. Elevated leptin levels are associated with excess gains in fat mass in girls, but not boys, with type 1 diabetes: longitudinal study during adolescence. J Clin Endocrinol Metab 2001;86:118893.
  • 71
    Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care 2007;30: 85460.
  • 72
    Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, Wagner OF et al. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes. Eur J Clin Invest 2006; 36:34552.
  • 73
    Kautzky-Willer A, Krssak M, Winzer C, Pacini G, Tura A, Farhan S et al. Increased intramyocellular lipid concentration identifies impaired glucose metabolism in women with previous gestational diabetes. Diabetes 2003;52:24451.
  • 74
    Kautzky-Willer A, Prikoszovich Th, Winzer Ch, Schmid AI, Szendrödi J, Chmelik M et al. Changes of mitochondrial function and hepatocellular lipid content in relation to insulin sensitivity in women with a history of gestational diabetes. Diabetologia 2008;51(Suppl 1):20.
  • 75
    Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:66471.
  • 76
    Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:3847.
  • 77
    Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:160916.
  • 78
    Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004;47:13609.
  • 79
    Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:12128.
  • 80
    Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008;5(Suppl A):S310.
  • 81
    Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol 2009;296:F6808.
  • 82
    Schultz CJ, Konopelska-Bahu T, Dalton RN, Carroll TA, Stratton I, Gale EA et al. Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford regional prospective study group. Diabetes Care 1999;22:495502.
  • 83
    Sibley SD, Thomas W, De Boer I, Brunzell JD, Steffes MW. Gender and elevated albumin excretion in the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) cohort: role of central obesity. Am J Kidney Dis 2006;47:22332.
  • 84
    Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 2005;289:F9418.
  • 85
    Cherney DZ, Sochett EB, Miller JA. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int 2005;68:17228.
  • 86
    Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:240713.
  • 87
    Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:181121.
  • 88
    Choi HK, Ford ES. Haemoglobin A1, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels–the third national health and nutrition examination survey. Rheumatology 2008;47:7137.
  • 89
    Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Ilanne-Parikka P et al. Serum uric acid as a harbinger of metabolic outcome in patients with impaired glucose tolerance: the Finnish diabetes prevention study. Diabetes Care 2006;29:70911.
  • 90
    Esposito K, Giugliano F, Ciotola M, De Sio M, D’Armiento M, Giugliano D. Obesity and sexual dysfunction, male and female. Int J Impot Res 2008;20:35865.
  • 91
    Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndrome and insulin resistance in a population with organic erectile dysfunction. J Sex Med 2005;2:96103.
  • 92
    Corona G, Mannucci E, Forti G, Maggi M, Hypogonadism ED. metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009; doi: DOI: 10.1111/j.1365-2605.2008.00951.x.
  • 93
    Rosen RC, Wing RR, Schneider S, Wadden TA, Foster GD, West DS et al. Erectile dysfunction in type 2 diabetic men: relationship to exercise fitness and cardiovascular risk factors in the Look AHEAD trial. J Sex Med 2009;6:141422.
  • 94
    Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol 2005;63:38194.
  • 95
    Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008;93:13946.
  • 96
    Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med 2009;6(Suppl 3):25461.
  • 97
    Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:12917.
  • 98
    Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004;27:2898904.
  • 99
    Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003;163:173540.
  • 100
    Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med 2005;165:4305.
  • 101
    Kawamoto R, Tomita H, Inoue A, Ohtsuka N, Kamitani A. Metabolic syndrome may be a risk factor for early carotid atherosclerosis in women but not in men. J Atheroscler Thromb 2007;14:3643.
  • 102
    Takahashi K, Bokura H, Kobayashi S, Iijima K, Nagai A, Yamaguchi S. Metabolic syndrome increases the risk of ischemic stroke in women. Intern Med 2007;46:6438.
  • 103
    Duggirala MK, Cuddihy RM, Cuddihy MT, Nyman MA, Naessens JM, Pankratz VS. Women with diabetes have poorer control of blood pressure than men. J Womens Health 2005;14:41823.
  • 104
    Ferrara A, Mangione CM, Kim C, Marrero DG, Curb D, Stevens M et al. Sex disparities in control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes: translating research into action for diabetes (TRIAD) study. Diabetes Care 2008;31:6974.
  • 105
    Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the women’s health study. Eur Heart J 2007;28:293743.
  • 106
    Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The western new york study. Diabetes Care 2007;30:3549.
  • 107
    Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:8139.
  • 108
    Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:155762.
  • 109
    Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002;53:6727.
  • 110
    He J, Gu D, Chen J, Jaquish CE, Rao DC, Hixson JE et al. Gender difference in blood pressure response to dietary sodium intervention in the GenSalt study. J Hypertens 2009;27:4854.
  • 111
    Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the general practice research database. Diabetologia 2006;49:285965.
  • 112
    Vagnerova K, Koerner IP, Hurn PD. Gender and the injured brain. Anesth Analg 2008;107:20114.
  • 113
    Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:254559.
  • 114
    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:256072.
  • 115
    Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 2008;23:1729.
  • 116
    Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes. Expert Opin Drug Safe 2008;7:6978.
  • 117
    Monami M, Cresci B, Colombini A, Pala L, Balzi D, Gori F et al. Bone fractures and hypoglycaemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008;31:199203.
  • 118
    Gerhat D. Evaluierung von geschlechtsspezifischen Unterschieden im Rahmen der Spätfolgen des Diabetes Mellitus Typ 2 mit Schwerpunkt auf Unterschiede im kardiovaskulären Risiko und den Beitrag des metabolischen Syndroms. Theses (University of Vienna, Institute of Pharmacology) 2008.
  • 119
    Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E. Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005;28:51420.
  • 120
    Nilsson PM, Theobald H, Journath G, Fritz T. Gender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care centres. Scand J Prim Health Care 2004;22:2731.
  • 121
    Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:2139.
  • 122
    Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293304.
  • 123
    Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 2008;294: R12204.
  • 124
    Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM. Impact of gender on statin efficacy. Curr Med Res Opin 2007;23:56574.
  • 125
    Ray JG, O’Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM 2001;94:43544.
  • 126
    Kitzmiller JL, Block JM, Brown FM, Catalano PM, Conway DL, Coustan DR et al. Managing pre-existing diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:106079.
  • 127
    Adlersberg MA, Burrow GN. Focus on primary care. Thyroid function and dysfunction in women. Obstet Gynecol Surv 2002;57(Suppl. 3):S17.
  • 128
    Hellmers C, Schuecking B. Primiparae’s well-being before and after birth and relationship with preferred and actual mode of birth in Germany and the USA. J Reprod Infant Psychol 2008;26:35172.
  • 129
    Banerjee M, Cruickshank JK. Pregnancy as the prodrome to vascular dysfunction and cardiovascular risk. Nat Clin Pract Cardiovasc Med 2006;3:596603.
  • 130
    Gasic S, Winzer Ch, Bayerle-Eder M, Roden A, Pacini G, Kautzky-Willer A. Impaired cardiac autonomic function in women with prior gestational diabetes mellitus. Eur J Clin Invest 2007;37: 427.
  • 131
    Mittermayer F, Kautzky-Willer A, Winzer C, Krzyzanowska K, Prikoszovich T, Demehri S et al. Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J Intern Med 2007;261:3928.
  • 132
    Jones RH, Ozanne SE. Fetal programming of glucose-insulin metabolism. Mol Cell Endocrinol 2009;297:49.
  • 133
    Dabelea D, Hanson RL, Lindsay RS, Pettitt DJ, Imperatore G, Gabir MM et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 2000;49:220811.
  • 134
    Hocher B. Fetal programming of cardiovascular diseases in later life – mechanisms beyond maternal undernutrition. J Physiol 2007;579:28788.
  • 135
    Thone-Reineke C, Kalk P, Dorn M, Klaus S, Simon K, Pfab T et al. High-protein nutrition during pregnancy and lactation programs blood, pressure, food efficiency, and body weight of the offspring in a sex-dependent manner. Am J Physiol Regul Integr Physiol 2006;291:R102530.
  • 136
    McCurdy CE, Bishop JM, Williams SM, Grayson BE, Smith MS, Friedman JE et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009;119:32335.
  • 137
    Hershkovitz D, Burbea Z, Skorecki K, Brenner BM. Fetal programming of adult kidney disease: cellular and molecular mechanisms. Clin J Am Soc Nephrol 2007;2:33442.
  • 138
    Maric C. Mechanisms of fetal programming of adult hypertension: role of sex hormones. Hypertension 2007;50:6056.
  • 139
    Grigore D, Ojeda NB, Alexander BT. Sex differences in the fetal programming of hypertension. Gend Med 2008;5(Suppl. A):S12132.
  • 140
    Mueller BR, Bale TL. Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci 2008;28:905565.
  • 141
    Xiao D, Xu Z, Huang X, Longo LD, Yang S, Zhang L. Prenatal gender-related nicotine exposure increases blood pressure response to angiotensin II in adult offspring. Hypertension 2008;51: 123947.
  • 142
    Schoenau E, Neu CM, Rauch F, Manz F. The development of bone strength at the proximal radius during childhood and adolescence. J Clin Endocrinol Metab 2001;86:6138.
  • 143
    Lagström H, Hakanen M, Niinikoski H, Viikari J, Rönnemaa T, Saarinen M et al. Growth patterns and obesity development in overweight or normal-weight 13-year-old adolescents: the STRIP study. Pediatrics 2008;122:e87683.
  • 144
    Campbell KJ, Crawford DA, Salmon J, Carver A, Garnett SP, Baur LA. Associations between the home food environment and obesity-promoting eating behaviors in adolescence. Obesity 2007;15:71930.
  • 145
    Faith MS, Berkowitz RI, Stallings VA, Kerns J, Storey M, Stunkard AJ. Parental feeding attitudes and styles and child body mass index: prospective analysis of a gene-environment interaction. Pediatrics 2004;114:e42936.
  • 146
    Trost SG, Kerr LM, Ward DS, Pate RR. Physical activity and determinants of physical activity in obese and nonobese children. Int J Obes Relat Metab Disord 2001;25:8229.
  • 147
    Buinauskiene J, Baliutaviciene D, Zalinkevicius R. Glucose tolerance of 2- to 5-yr-old offspring of diabetic mothers. Pediatr Diab 2004;5:1436.
  • 148
    Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: the role of intrauterine hyperglycemia. Diabetes Care 2008;31:3406.
  • 149
    Tam WH, Ma RC, Yang X, Ko GT, Tong PC, Cockram CS et al. Glucose intolerance and cardiometabolic risk in children exposed to maternal gestational diabetes mellitus in utero. Pediatrics 2008;122:122934.
  • 150
    Pettitt DJ, Lawrence JM, Beyer J, Hillier TA, Liese AD, Mayer-Davis B et al. Association between maternal diabetes in utero and age at offspring’s diagnosis of type 2 diabetes. Diabetes Care 2008;31:212630.